Cardiogen (sequence: Ala-Glu-Asp-Arg / AEDR) is a synthetic tetrapeptide bioregulator. It belongs to the well-known "Khavinson peptide class," originating from research on natural regulatory peptides in myocardial tissue. Unlike traditional cardiovascular drugs, it does not act directly on cell surface receptors but is believed to penetrate the cell nucleus, regulating the expression of heart-specific genes through interactions with DNA and histones, thereby supporting cardiomyocyte repair, survival, and functional maintenance.
Research Background: Developed in the 1980s and 1990s by Professor Vladimir Khavinson's team at the Institute of Bioregulation and Gerontology, St. Petersburg, Russia. Researchers isolated and identified the shortest and most bioactive core tetrapeptide sequence from a mixture of peptides (Cytomaxes) extracted from the myocardial tissue of young animals.
Research History: Early research focused primarily on organoid myocardial tissue culture and rodent models, exploring its effects on cardiomyocyte proliferation, anti-apoptosis, and anti-aging. Currently, it is mainly used in the biological regulator systems of the former Soviet Union and has not yet received drug approval from mainstream Western drug regulatory agencies such as the FDA or EMA.
Dual Potential Research (Focus for 2026): Recent studies, in addition to focusing on its cardioprotective function, have also discovered its "selective dual action" in the tumor microenvironment. Specifically, it inhibits apoptosis (protection) in healthy myocardium by downregulating p53, while in certain tumor models (such as rat M-1 sarcoma) it can induce tumor cell apoptosis and inhibit angiogenesis, making it a research hotspot targeting the tumor microenvironment.
Limitations in Clinical Translation: Although some Russian literature mentions clinical observations, as of 2026, there is still a lack of large-scale, internationally standardized, peer-reviewed human clinical trial data from Western countries.
Sequence: H-Ala-Glu-Asp-Arg-OH (AEDR).
Molecular Formula: C₁₈H₃₁N₇O₉.
Molecular weight: Approximately 489.48 Da.
Appearance: White or off-white lyophilized powder.
Solubility: Easily soluble in water or antibacterial aqueous solution (BAC).
Storage: Lyophilized powder can be stored long-term (up to 2 years) at -20°C, and for several months at 2-8°C; after reconstitution, it should be stored at 2-8°C protected from light, and is generally recommended to be used within 30 days.
Note: The following dosages are based on research community and biological modulatory therapy protocols and are not standardized drug dosages.
Subcutaneous injection (common research protocol): 10-20 mg every 3-7 days; or 1-2 mg once daily. The course of treatment is usually 10-20 days, with 2-4 cycles per year.
Oral/sublingual (Cytomaxes tablets): 200 μg - 20 mg once daily on an empty stomach, for a course of treatment of 10-30 days. Reconstitution: Reconstitute the lyophilized powder using 1-3 mL of antibacterial aqueous solution (BAC) with gentle swirling; avoid vigorous shaking.
Epigenetic Regulation: Penetrates the cell nucleus, binds to specific regions of DNA and histones (H1, H2b, H3, H4), altering chromatin structure and thereby activating the transcription of heart-specific genes (such as cytoskeletal proteins and nuclear matrix proteins).
Anti-apoptosis (Heart): Downregulates p53 protein expression, inhibiting programmed cell death in cardiomyocytes, especially protecting the myocardium under ischemic or aging stress.
Proliferation and Anti-fibrosis: Stimulates the proliferative potential of cardiomyocytes (even aging cells) while regulating fibroblast activity, potentially reducing pathological scar (fibrosis) formation and improving remodeling.
Metabolic and Mitochondrial Support: Studies show it can protect mitochondrial structure, maintain myocardial glycogen reserves and energy metabolism, and enhance antioxidant defense.
Tissue Specificity: Exhibits high selectivity for cardiac tissue, primarily acting on cardiomyocytes and cardiac fibroblasts, with weaker effects on non-target tissues (such as the brain and thymus).
Root Cause Regulation: Aims to "restore normal gene expression" rather than simply blocking/activating receptors, theoretically improving cardiac resilience at the cellular aging level.
Pleiotropy: Possesses protective (anti-apoptotic, antioxidant), repair (anti-fibrotic), and potential anti-tumor microenvironment modulation capabilities.
Safety Overview: As an ultrashort peptide composed of common amino acids, it is expected to be degraded by normal protein hydrolysis; preclinical studies have not reported significant acute toxicity.
Low Level of Evidence: All data are almost entirely derived from cell experiments and rodent models, or limited to a single research network; there are no large-scale Western human clinical trials, and efficacy has not been validated.
Unapproved as a Drug: Not approved by the FDA/EMA for therapeutic use; in most countries, it exists only as an "investigation chemical" or dietary supplement ingredient.
Theoretical risks of p53 inhibition: Due to the involvement of p53 pathway downregulation (although tissue-specific), there are theoretical concerns about carcinogenicity or abnormal cell proliferation, which have not been ruled out in long-term toxicology studies.
Inconvenient administration: Injection regimens require subcutaneous administration and refrigeration; oral bioavailability may fluctuate.
Unknown interactions: Interactions with common cardiovascular drugs (such as warfarin, digoxin, etc.) have not been systematically studied.
Cardiovascular anti-aging: Used to study interventions for age-related decline in cardiac function and age-related cardiomyocyte loss in older adults.
Postoperative/post-infarction support: In Russian biomodulation therapy, sometimes used for rehabilitation support after myocardial infarction or cardiac surgery (requires physician supervision and cannot replace standard treatment).
Cardiac function maintenance: Research support for decreased exercise tolerance and chronic myocardial ischemia.
Research use: As a cardiac-specific biomodulator, used in cell biology, epigenetics, and tissue engineering research.
Tissue Culture Studies: Chalisova et al. (2009) found that at picomolar concentrations, Cardiogen stimulated cardiomyocyte proliferation in the myocardial tissue of 3-month-old (young) and 24-month-old (aged) rats and reduced p53 expression, while single amino acids had no such effect.
Animal Models: In a rat coronary artery ligation (myocardial infarction) model, the Cardiogen treatment group showed a significant reduction in mortality (approximately 3-fold), a smaller necrotic area, and increased glycogen retention.
Clinical Observations (Russian Literature): Lin A.A. et al. (2011) reported that after use in patients with coronary artery disease, echocardiography showed an increase in left ventricular ejection fraction (LVEF), improved exercise tolerance, and reduced angina.
Contraindications: Pregnant/lactating women (no safety data), children (open epiphyses/developing), known peptide allergies, and those experiencing acute heart failure (not a substitute for emergency care).
Cancer History: Due to its involvement in cell proliferation and p53 modulation, this product should be avoided in patients with active cancer unless evaluated by an oncologist.
Monitoring Recommendations: For investigational human trials, baseline and follow-up monitoring of electrocardiogram (ECG), cardiac biomarkers (such as BNP and troponin), and heart rate variability (HRV) is recommended.
Injection Safety: Use aseptic technique, rotate injection sites (abdomen, thigh), and do not use if the solution is cloudy after reconstitution.
Non-Medical Advice: This is currently an investigational compound. Any use should be performed by a qualified professional, and prescribed cardiovascular medications should not be discontinued without medical advice.
Hot Tags: Peptide drug Cardiogen 20mg/vial, China Peptide drug Cardiogen 20mg/vial manufacturers, suppliers, factory
